Welcome to our dedicated page for Zentalis Pharmaceuticals SEC filings (Ticker: ZNTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as it advances azenosertib, an investigational WEE1 inhibitor, through clinical development. As a clinical-stage biopharmaceutical issuer, Zentalis files Forms 10-K and 10-Q for annual and quarterly reporting, along with Form 8-K current reports detailing material events related to its oncology programs, financial position and corporate governance.
Recent Form 8-K filings describe financial results and operational progress, including updates on the DENALI Phase 2 trial in Cyclin E1-positive platinum-resistant ovarian cancer (PROC), cash, cash equivalents and marketable securities levels, and the company’s view of its operational runway. Other 8-Ks report leadership and board changes, such as transitions in the Chief Legal Officer and Corporate Secretary role, a director resignation with a corresponding reduction in board size, and a stock repurchase from a major shareholder. These filings often incorporate press releases by reference, providing additional detail on clinical and corporate developments.
Investors can also review disclosures related to stockholder meetings and voting results, such as the annual meeting outcomes for director elections, auditor ratification and advisory votes on executive compensation. Equity compensation arrangements, including inducement stock option grants under the company’s employment inducement incentive award plan, are reported in connection with Nasdaq Listing Rule 5635(c)(4).
On Stock Titan, ZNTL filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand how Zentalis’ SEC reports address azenosertib’s clinical status, biomarker-driven strategy, cash resources and governance matters. Users can track new filings in real time as they are posted to EDGAR, and use these insights alongside news and market data to build a more complete picture of Zentalis’ risk profile and development trajectory.
Zentalis Pharmaceuticals reported an equity award to its Chief Legal Officer, James B. Bucher. He received a stock option grant covering 100,000 shares of common stock at an exercise price of $2.84 per share. The options were granted on January 8, 2026 and are held directly. Following this grant, Bucher beneficially owns 100,000 stock options.
The options will vest over four years in substantially equal monthly installments, and vesting is conditioned on his continued service with the company. This is a compensatory award rather than an open-market purchase or sale.
Zentalis Pharmaceuticals, Inc. reported that its Chief Medical Officer, Ingmar Bruns, received a grant of stock options on 01/08/2026. The award covers 365,000 stock options with an exercise price of $2.84 per share and an expiration date of 01/07/2036. Each option is exercisable for one share of common stock, giving potential access to 365,000 shares if exercised in the future.
According to the filing, the options were granted at a price of $0 for the derivative security itself and are held directly by the reporting person. The options will vest over four years in substantially equal monthly installments, as long as Bruns continues to serve with the company, so ownership rights build gradually rather than all at once.
Zentalis Pharmaceuticals, Inc. reported an insider equity award for its CEO and President, Julia Marie Eastland, in a Form 4 filing. On January 8, 2026, she received a grant of stock options to buy 775,000 shares of the company’s common stock at an exercise price of $2.84 per share. These options were reported as held directly, with 775,000 derivative securities beneficially owned following the transaction.
According to the filing, the options will vest over four years in substantially equal monthly installments, and vesting is conditioned on her continued service with the company. There were no sales of stock reported; this filing reflects an award of options rather than a disposition of shares.
Zentalis Pharmaceuticals reported a corporate update focused on its lead cancer drug candidate azenosertib and its financial position. In 2025 the company completed enrollment in Part 2a of its Phase 2 DENALI trial in platinum-resistant ovarian cancer, aligned with the FDA on the design of the confirmatory ASPENOVA Phase 3 trial, and reported strong data across three PROC trials supporting Cyclin E1-positive disease as the lead indication. As of September 30, 2025, Zentalis held $280.7 million in cash, cash equivalents and marketable securities and believes this provides runway into late 2027. For 2026, it expects DENALI Part 2a dose confirmation and ASPENOVA Phase 3 initiation in the first half of the year and a DENALI Part 2 topline readout by year end 2026, which it states could support a potential accelerated approval, subject to FDA feedback.
Zentalis Pharmaceuticals director-affiliated entity The Walters Group purchased 6,459,973 shares of the company’s common stock at $1.20 per share. This transaction on 12/31/2025 increased the entity’s holdings to 13,509,973 shares of Zentalis common stock. The filing identifies The Walters Group as the direct holder of the shares, while William T. Walters and Susan B. Walters may be deemed to share voting and dispositive power through their roles with the entity. Each reporting person disclaims beneficial ownership of the reported shares except to the extent of any pecuniary interest.
Zentalis Pharmaceuticals filed an initial ownership report showing that The Walters Group directly holds 7,050,000 shares of the company’s common stock. Footnotes explain that William T. Walters and Susan B. Walters may be deemed to share voting and dispositive power over these shares through The Walters Group, but each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.
The filing also notes that Zentalis entered into a Stock Purchase Agreement with Matrix Capital Master Fund, LP to repurchase 7,500,000 shares of its common stock, with the repurchase closing on December 15, 2025. As a result of this repurchase, the reporting persons are deemed to be 10% holders, and this status did not arise from any new acquisition of securities by them.
Zentalis Pharmaceuticals, Inc. (ZNTL) disclosed a large insider sale by entities affiliated with Matrix Capital Management Company, LP and its managing general partner, David E. Goel. On 12/15/2025, the reporting persons sold 7,500,000 shares of Zentalis common stock at $1.33 per share in an open market or private sale transaction coded "S".
After this transaction, they reported 6,459,973 shares of Zentalis common stock beneficially owned on an indirect basis, held through Matrix Capital Management Master Fund, LP. The reporting persons, including the investment manager and Mr. Goel, expressly disclaim beneficial ownership of these securities except to the extent of their pecuniary interest.
Zentalis Pharmaceuticals agreed to repurchase 7,500,000 shares of its common stock from Matrix Capital’s fund at $1.33 per share, below the recent $1.40 closing price. The buyback, which closed on December 15, 2025, is tied to Matrix Capital Management’s previously announced plan to wind down its family of funds.
The company states that this repurchase is not expected to materially affect its projected cash runway into late 2027. On the same date, Karan Takhar, a Matrix executive, resigned from Zentalis’ Board of Directors and all board committees, with the company noting there was no disagreement over operations or policies. Following his departure, the board size was reduced from seven to six directors.
Zentalis Pharmaceuticals (ZNTL) filed its Q3 2025 report, highlighting lower operating spend and a solid cash position while advancing azenosertib in ovarian cancer. The company reported a Q3 net loss of $26.7 million on operating expenses of $33.7 million, driven by R&D $23.0 million and G&A $10.8 million. Investment and other income contributed $7.0 million in the quarter.
Cash, cash equivalents and marketable securities totaled $280.7 million as of September 30, 2025, and management believes this will fund operations into late 2027. Year to date, the company recorded $7.8 million in restructuring charges tied to a roughly 40% workforce reduction. Shares outstanding were 72,250,779 as of November 1, 2025.
Development continues on azenosertib (WEE1 inhibitor) in Cyclin E1‑positive platinum‑resistant ovarian cancer. DENALI Part 2 is enrolling, with topline data anticipated by year end 2026, and a Phase 3 confirmatory study is planned to run concurrently with Part 2b. The company noted that the October 1, 2025 U.S. government shutdown could delay FDA and SEC timelines.
Zentalis Pharmaceuticals (ZNTL) furnished an update via Form 8-K. The company announced its financial results for the quarter ended September 30, 2025, and provided business updates. A press release was furnished as Exhibit 99.1 and a corporate presentation as Exhibit 99.2, both beginning November 10, 2025. The materials under Items 2.02 and 7.01 are furnished, not filed, and are not subject to Section 18 liabilities or automatically incorporated by reference.